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A b s t r a c t
Background: Interventional cardiology and electrophysiology are disciplines with a growing number of complex procedures, 
which are exposed to the occurrence of many complications.
Aim: To assess efficacy and legitimacy of the periprocedural checklist in prevention of cardiovascular adverse events, in elec-
tive patients undergoing invasive diagnostic and treatment. 
Methods: A total of 2064 patients directed to treatment in the catheterisation laboratory between May 2011 to August 2012 were 
analysed. Patients who were hospitalised without invasive diagnostics and treatment were not included in the study. Patients 
were divided into two groups: a control group — 1011 patients with invasive diagnostics and treatment before introduction of 
periprocedural checklist; and an intervention group — 1053 patients with invasive diagnostics and treatment after introduc-
tion of periprocedural checklist. We analysed the studied groups, assessing adverse events associated with hospitalisation and 
performed procedures. We also conducted subjective evaluation of checklists by medical staff on the basis of a questionnaire.
Results: Baseline characteristics between the studied groups were comparable except for a higher rate of stable coronary artery 
disease (50.7% vs. 39.6%, p £ 0.001) and electrophysiology procedures in the control group. Implementation of a checklist was 
favourable in cases of decreased adverse events (6.8% vs. 3.9%, p = 0.004) especially bleedings (2.3% vs. 0.3%, p < 0.001). 
Multivariate analysis confirmed that lack of a periprocedural checklist during hospitalisation was an independent factor as-
sociated with a higher rate of adverse events (OR = 2.97, 95% CI 1.60–5.53, p = 0.001). Subjective evaluation of medical 
staff opinions showed that implementation of a checklist seems to be associated with improved communication skills, work 
organisation, prevention of the occurrence of medical errors, and reduced rate of complications associated with procedures.
Conclusions: Introduction of a periprocedural checklist was associated with significant reduction of adverse events among 
patients undergoing invasive procedures. It also showed a positive influence on team communication, and organisation and 
quality of treatment, according to the opinions of medical staff. 
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INTRODUCTION
Modern cardiology wards equipped with a Catheterisation 
Laboratory have to face rising requirements, which are 
associated with the rapid development of cardiology and 
electrophysiology in recent years. The wide spectrum of 
procedures inevitably increases the risk of unintended errors 
committed by physician and nurses. The estimated percentage 
of complications occurring during these procedures is around 
3.36% for percutaneous coronary interventions (PCI) and 4% 
for electrophysiology procedures, and partially depends on 
whether the procedures are planned or urgent [1, 2]. Some 
of adverse events cannot be avoided; however, some of them 
could be caused by a lack of proper communication by medi-
cal staff or sufficient attention devoted to the patient during 
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particular stages of treatment. It seems that a solution that 
could be helpful in the optimisation of therapeutic process 
safety is the introduction of a periprocedural checklist. The 
whole concept was derived from airline pilot procedures, 
where it is used to minimise the risk of human-derived er-
rors. The efficacy of the checklist in medicine was confirmed 
in surgery. A prospective multi-centre study showed that the 
introduction of a checklist was associated with a significant 
reduction in mortality (1.5% vs. 0.8%, p = 0.003) and compli-
cations (11% vs. 7.0%, p < 0.001) among patients undergoing 
surgical procedures [3].
Current European Society of Cardiology (ESC) and 
American Heart Organisation (AHA) guidelines do not con-
tain recommendations suggesting the use of checklists on 
interventional cardiology wards; however, its construction for 
minimising human error and to prevent complications during 
interventional procedures was suggested in literature, but as 
yet no study has been conducted to asses its influence on 
treatment outcomes and complications [4, 5].
The aim of this study was to assess the efficacy and 
legitimacy of the periprocedural checklist in the prevention 
of adverse cardiovascular events in elective patients undergo-
ing invasive cardiology and electrotherapy treatment before 
and after its introduction in a cardiology ward. Additionally, 
we evaluated subjective importance, and relevance in treat-
ment process and work organisation of the checklist among 
medical staff.
METHODS
We conducted a retrospective analysis of consecutive patients 
admitted to the Department of Cardiovascular Diseases in the 
Silesian Centre for Heart Diseases before and after checklist 
introduction. We included only patients with stable coronary 
artery disease because our department does not have an 
emergency room for patients with acute myocardial infarc-
tion. The ward is equipped with 42 beds, including 12 in-
tensive care units. The catheterisation laboratory is provided 
with access to the medical devices necessary to perform the 
whole spectrum of coronary, electrotherapeutic, and electro-
physiology procedures. All patients who underwent invasive 
diagnostic and treatment were included in the analysis and 
were subsequently divided into two groups: a control group 
-— patients with invasive diagnostics and treatment before the 
introduction of the periprocedural checklist; and an interven-
tion group — patients with invasive diagnostic and treatment 
after the introduction of the periprocedural checklist. Patients 
who were hospitalised in the ward without invasive proce-
dures were not included in the study. Data regarding treatment 
process, performed procedures, and occurred complications 
were obtained from prospectively collected Central Database 
of Electronic Medical History and IT system of the Silesian 
Centre of Heart Diseases in Zabrze. Every adverse event 
observed in database was verified by inspection of medical 
history. All patients were pharmacologically treated according 
to current ESC guidelines.
Evaluation of the periprocedural checklist was performed 
on the basis of a questionnaire. The study included doctors, 
nurses, and medical technicians. It excluded persons who 
were employed after the introduction of the cardiology check-
list to everyday practice and respondents whose answers were 
incomplete or imprecise. The method employed in this study 
was the diagnostic poll method; data were collected by means 
of a survey given to the participants, which contained a set of 
close-ended questions. All respondents were asked the same 
questions, concerning the periprocedural safety checklist and 
its influence on work organisation, communication, and the 
quality of care.
Intervention
The intervention involved implementation of the peripro-
cedural checklist, which was prepared on the basis of the 
Cardiology and Cardiovascular Diseases Department’s work 
characteristics. The checklist scheme represents following the 
steps of the patient’s preparation for invasive diagnostics and 
treatment. A full version of the document is available in the 
Appendix 1. In brief, the checklist consists of four parts. The 
first part contains information about the type of planned pro-
cedure, conducted tests, current laboratory parameters and 
pharmacological treatment, patient allergies, preferred periph-
eral access, type of stent to be used, and consent to treatment 
signed by the patient. This part is authorised and signed by the 
physician. Subsequently, a periprocedural checklist is passed 
to the nurse on the ward, who fills in the section focused on 
the patient’s preparation for the procedure. Afterwards the pa-
tient is transferred to the catheterisation/electrophysiological 
laboratory, where nurse and operator check his/her prepara-
tion, familiarise themselves with the information contained in 
the document, and confirm it with their signatures. The third 
part, complemented and signed by operator, includes data 
on the type and course of the procedure and also recommen-
dations about further postprocedural care on the ward. The 
last part of the periprocedural checklist is designed to keep 
or in some cases modify the advice given by both the nurse 
and the physician on the ward. After patient discharge it is 
archived in the hospital database. This document refers to the 
whole course of the patient trough the diagnostic or treatment 
process including preparation, performing procedure/s, and 
the subsequent care. Immediately before the introduction of 
the periprocedural checklist, all personnel participating in the 
treatment process were carefully trained in fields complement-
ing particular sections and interpretation of recommendations 
included in the document. Implementation of the mentioned 
instrument was preceded by a two-week probation period, 
during which the study team explained every concern and de-
termined the final procedure of logistics. Optimisation of the 
treatment program was finally launched in November 2011. 
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Definition
For the purposes of the study, the endpoint was defined as 
the occurrence of major adverse cardiac and cardiovascular 
events (MACCE) during the treatment process, until discharge. 
The primary outcome measures consisted of: all bleedings, 
stroke/transient ischaemic attack (TIA), myocardial infarction, 
repeat PCI, and death. Moreover, we analysed separately 
any bleeding complications. Definitions were as follows: all 
bleedings — any bleeding which occurred during hospitali-
sation; stroke/TIA — neurological deficit of cerebrovascular 
cause that persisted beyond 24 h or was interrupted by death 
within 24 h, which is defined to last less than 24 h; repeat PCI 
— every subsequent revascularisation procedure; myocardial 
infarction — either new, abnormal Q waves and one ratio 
of peak creatine kinase-MB (CK-MB)/peak total CK > 10%, 
or new, abnormal Q-waves and one plasma level of CK-MB 
5 × the upper limit for normal; death — death for any reason, 
all deaths were considered cardiac unless an unequivocal 
non-cardiac cause can be established. 
Statistical analysis
Comparative analysis of the studied groups included: baseline 
clinical characteristics, types of performed procedures, and 
occurred complications. Distribution of quantitative variables 
was evaluated with Shapiro-Wilks test. Due to significant 
derogations from normal distribution, U-Mann-Whitney 
test was used. The results of quantitative analysis are listed 
as the arithmetic mean and standard deviation. Qualitative 
parameters were analysed using Pearson’s c2 test. Analysis 
of factors influencing the occurrence of adverse events was 
conducted with logistic regression, and model reduction was 
conducted using stepwise regression. Results were listed as 
odds ratio (OR) and 95% confidence interval (CI). The level of 
statistical significance was p < 0.05 (two-tailed). STATISTICA 
10 software (StatSoft, Inc., Tulsa, OK, USA).
RESULTS
A total of 2064 patients were enrolled in the study: the control 
group consist of 1011 patients, and intervention group consisted 
of 1053 patients.  Baseline characteristics with regard to the lead-
ing medical diagnosis at admission and comorbidities are shown 
in Table 1. In the period before the introduction of the peripro-
cedural checklist there was a significantly higher rate of patients 
with diagnosed stable coronary artery disease in the control 
group (50.7% vs. 39.6%, p ≤ 0.001). Patients’ ages were com-
parable in both studied groups (63.7 ± 10.4 vs. 63.3 ± 10.4, 
p = 0.2). Characteristics of performed invasive procedures are 
presented in Table 2. After introduction of the checklist we 
performed a significantly higher rate of cardioverter implanta-
tions, and fewer resynchronisation and right heart catheterisation 
procedures (respectively: 5.7% vs. 10.5%, p = 0.001; 5.7% 
vs. 3.7%, p = 0.03; 4.1% vs. 2.3%, p = 0.03). The number of 
ablations was relatively small in both study periods. 
Study endpoint analysis showed a significantly smaller 
rate of combined adverse cardiac events in the intervention 
group (3.0% vs. 0.9%, p = 0.001). The results of adverse 
events rates in in-hospital observation are presented in 
Table  3. Multivariate analysis confirmed that the lack of 
a periprocedural checklist during hospitalisation was an 
independent factor associated with a higher rate of adverse 
events, together with diagnosis of stable coronary artery dis-
ease, valvular heart disease, atrial fibrillation at admission, 
and age of patients (Table 4). 
Detailed data regarding the subjective importance of the 
survey were published elsewhere [6]. In brief, evaluation of 
the periprocedural checklist was performed by 85 persons: 
31 doctors, 46 nurses, and 8 medical technicians. More than 
80% of physicians and nurses found that implementation of 
the checklist was legitimate. Summarising, we could state that 
its implementation improved communication skills and work 
organisation in both the cardiology ward and the catheterisa-
tion laboratory, prevented the occurrence of medical errors, 
and reduced the rate of complications associated with the 






Hypertension 70.2% 69.5% 0.8
Stable coronary  
artery disease 
50.7% 39.6% 0.0001
Heart failure 28.4% 30.1% 0.4
Acquired heart defects 24.7% 21.0% 0.06
Atrial fibrillation 18.8% 16.9% 0.3
Complex ventricular  
arrhythmias
4.9% 3.4% 0.1
Atrial flutter 1.1% 1.1% 0.9
Congenital heart defect 1.3% 0.9% 0.4

















Right heart catheterisation 4.1% 2.3% 0.03
Ablation 0.7% 0.3% 0.3
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procedure. Moreover, a significant proportion of personnel 
declared that it facilitated patient periprocedural care and also 
improved physicians’ and nurses’ quality care. The checklist 
precisely defines personnel tasks and specifies responsibili-
ties. In the opinion of medical staff, implementation of the 
periprocedural checklist was legitimate.
DISCUSSION
Introduction of the periprocedural checklist decreased the rate 
of complications related to performed invasive cardiology and 
electrophysiology procedures. The positive effect observed 
after checklist implantation resulted principally from reduction 
of bleedings, especially from vascular access sites (relative risk 
reduction 83%). We did not observe significant differences 
in ischaemic complication rates. The positive impact of the 
periprocedural checklist on the occurrence of MACCE was 
confirmed in multivariate analysis. 
The primary concept that encouraged the study team 
to introduce the periprocedural checklist was the assump-
tion that a significant number of complications associated 
with invasive procedures could be caused by unintended 
mistakes and lack of proper team communication. The ef-
ficacy of the checklist was evaluated on a cardiology ward in 
which every type of interventional cardiology procedure is 
performed. Heterogeneity of the conducted procedures could 
cause unconscious omission of important aspects regarding 
periprocedural care by medical personnel. Considering the 
profile of the treated patients and the type of conducted 
interventions, during construction of the checklist we paid 
particular attention to aspects potentially connected with 
the occurrence of bleedings. It is known that bleeding com-
plications determine patient prognosis to the same degree as 
ischaemic complications.  
A number of studies have shown that bleeding com-
plications after PCI are associated with adverse outcome 
[7–10]. Kinnaird et al. [10] observed that bleeding after PCI 
was associated with longer hospital stay (8.9 vs. 3.1 days, 
p < 0.001) and higher in-hospital and one-year mortality. In 
the multivariate regression analysis Thrombolysis in Myocar-
dial Infarction, major bleeding after PCI was an independent 
predictor of in-hospital mortality [10]. These findings were 
confirmed in the large NHLBI Dynamic Registry, in which 
patients experiencing access-site haematomas requiring 
transfusions were nine times more likely to die during hospi-
talisation (1.2% vs. 9.9%; OR 9.32; 95% CI 4.93–17.63) [9]. 
In the REPLACE study assessing antithrombotic regiment with 
bivalirudin ± glycoprotein (GP) IIb/IIIa inhibitors, patients with 
major haemorrhage had significantly higher mortality rates at 
30 days, and at 6 and 12 months. Major bleeding was found 
to be an independent predictor of one-year mortality [11].
The potential mechanisms underlying the association 
between bleedings and outcomes are multifactorial. Most 
obvious causes are: hypovolaemia, anaemia, hypotension, 
and diminished oxygen-carrying capacity from acute blood 
loss. The next factor is blood transfusion, which somehow 
increases the risk of adverse events among patients with major 
bleeding complications [10]. The reason for this correlation 
remains unclear [12]. 
Different strategies may be applied to diminish the risk 
of bleeding complications. The most important are opti-
misation of periprocedural pharmacology and procedural 
access site assessment. Unfractionated heparin (UFH) is 
the most common antithrombotic drug. There is a direct 
correlation between antithrombotic power assessed with 
activated clotting time and the risk of bleeding and ischae-
mic complications [13]. There were a lot of studies assess-
ing different pharmacological strategies to reduce the risk 
of bleedings. In the STEEPLE trial low-molecular weight 
heparin (LMWH) was compered to UFH in 3528 patients 
undergoing elective PCI procedures. LMWH was given in 
two regimes: 0.5 mg/kg and 1.0 mg/kg. The rate of major 
bleedings was the lowest in the low-dose enoxaparin group 
(5.9% vs. 6.5% vs. 8.5% for 0.5 mg, 1.0 mg enoxaparin 
and UFH, respectively). However, the risk of ischaemic 






Bleedings 2.3% 0.3% 0.0001
Access point 1.8% 0.3% 0.001
Gastrointestinal tract 0.4% 0% NS










Death 0% 0% NS
Major adverse cardiac 
events — all
3.0% 0.9% 0.001







Lack of periprocedural checklist 2.97 1.60–5.53 0.001
Stable coronary artery disease 2.04 1.33–3.12 0.001
Valvular heart disease 1.92 1.28–2.90 0.001
Atrial fibrillation 1.67 1.00–2.77 0.05
Age 1.08 1.02–1.13 0.004
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risk by a factor of four [22]. Also, the use of heparin bridging 
to oral anticoagulation carries a substantial risk of bleeding; 
therefore, procedures with mild oral anticoagulation were 
proposed (international normalised ratio < 2.0) [23]. 
In the analysed population the primary effect of the in-
troduction of the checklist was a reduction in periprocedural 
bleeding complications. This seems to be associated with 
effective and critical assessment of applied anticoagulant, 
antiplatelet treatment and the vascular access site used. When 
preparing the study, we were focused on the course of patient 
preparations to the procedure and communication within the 
medical staff. Therefore we did not analyse periprocedural 
preparation regimens and pharmacotherapy but concentrated 
on the systemic solution for the improvement of patient safety. 
The results of our study encourage use of the checklist for this 
purpose. However, it cannot be ruled out that the Hawthron 
effect was partially responsible for the achieved results, in 
which improved quality is associated with the fact that the 
evaluated team is being observed [24]. In the presented study 
there is no possibility to determine how it affected improve-
ment of treatment quality.
Analysing subjective evaluation of periprocedural check-
list by medical staff, it can be stated that every occupation 
group (physicians and nurses) favourably evaluated imple-
mentation of this procedure. The checklist is a simple tool 
for reduction of periprocedural complications, which helps 
medical personnel to provide proper patient care. Introduc-
tion of the checklist is legitimate and well understood by the 
therapeutic team.
Limitations of the study
The main limitation of presented study is fact that it was a ret-
rospective analysis. Nevertheless, from the perspective of the 
reliability of the obtained data it could be an advantage, to 
some extent eliminating the impact of the Hawthrone effect. 
The therapeutic team was not aware that it would undergo 
quality assessment. Additionally, we did not collect data on 
pharmacology regimens, but in terms of the main principle of 
the study it was not an issue. Moreover, the results are derived 
from a single cardiology ward, which involves limitations typi-
cal for single-centre studies. 
CONCLUSIONS
Introduction of the periprocedural checklist was associated 
with a significant reduction in adverse events among patients 
undergoing invasive procedures, especially bleedings. It also 
had a positive influence on team communication, organisa-
tion, and quality of treatment, in the opinion of medical staff
Conflict of interest: none declared
complications was significantly higher in the low-dose 
enoxaparin group, which limited its widespread acceptance 
for PCI [14]. Another studied agent was bivalirudin. In the 
REPLACE-2 study 6010 patients undergoing elective and 
urgent PCI were assigned to UFH + GP IIb/IIIa inhibitors or 
bivalirudin with provisional GP IIb/IIIa. There was no differ-
ence in ischaemic adverse events frequency, but significant 
reductions in bleeding complications in the bivalirudin group 
were observed (2.4% vs. 4.1%, p < 0.001). The most com-
mon reason for major bleedings in this study was access site 
bleeding (2.5% vs. 0.8% for UFH and bivalirudin, respec-
tively) [15]. The strategy without antithrombotic treatment 
during simple elective PCI procedure was assessed in the 
CIAO trial [16]. A total of 700 patients on dual antiplatelet 
therapy were randomly assigned to either a standard group 
(UFH dose 70–100 UI/kg) or a no-heparin group. Bleeding 
complications were significantly lower in the no-heparin 
group (1.7% vs. 0.0%, p = 0.048). There were no differences 
in ischaemic events. Surprisingly, in the no-heparin group 
there was a significantly lower incidence of postprocedural 
CK-MB elevation (1.7% vs. 3.1%, p < 0.05) [16]. 
Access site bleedings are the most common complica-
tion of the transfemoral approach [15]. Therefore, changing 
the access site to the radial artery may be the most effective 
single procedural method to reduce bleedings. In a large mul-
ticentre study conducted by Jolly et al. [17], which compared 
radial vs. femoral approach in patients directed to invasive 
diagnostics or treatment, there was a significant reduction in 
large haematoma at 30 days in patients who underwent pro-
cedures from radial approach compared to femoral (hazard 
ratio [HR] 0.40, 95% CI 0.28–0.57, p < 0.0001). However, 
there were no statistical differences in primary endpoint, 
which was composite of death, myocardial infarction, stroke, 
or non-coronary artery bypass graft-related major bleeding 
at 30 days (HR 0.92, 95% CI 0.72–1.17, p = 0.50) [17]. 
Almost all studies comparing transradial and transfemoral 
approach show benefits in terms of bleedings in the radial 
groups [18–20]. The transradial approach seems to be the 
most effective among patients with increased risk of bleeding 
complications like acute coronary syndromes treated with 
potent antithrombotic agents or atrial fibrillations requiring 
oral anticoagulation [17]. 
Bleeding complications, especially haematomas, oc-
curred quite often after electrotherapy procedures, rang-
ing from 2.9% to 9.5% of cases [21]. Similarly to coronary 
procedures, anticoagulation and antiplatelet therapies are 
the most important issue. Aspirin therapy carries a two-fold 
risk of bleeding, and dual antiplatelet therapy increases that 
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Appendix 1. Periprocedural checklist 
First part
Preparation for the procedure on the ward
Planned procedure  Coronary angiography  Pressure measurement  Biopsy 
 PCI  ICD implantation  BIV-ICD implantation 
 EP test and ablation  Stimulator implantation  Other
Normal sinus rhythm  Yes  No 
ECHO test done  Yes  No 
Normal blood morphology  Yes  No 
Normal coagulation parameters  Yes  No 
Normal electrolytes level  Yes  No 
Normal renal parameters  Yes  No 
Signed consent to treatment  Yes  No 
Metformin discontinuation in patient  
directed to test with imaging contrast 
 Yes  No 
Pregnancy test  Yes  No 
Palpable pulse on artery: Radial  R   L  Femoral  R   L  Tibial post.  R   L  
Murmur in the groin Right   yes   no Left   yes   no
Current pharmacological treatment: 
Anticoagulant  Yes  No
 Unfractionated heparin  Low molecular weight heparin 
 Acenocoumarol/Warfarin Last dose ……………………… 
Antiplatelet  Yes  No
 ASA    Clopidogrel
Antibiotic allergies ………………………  Yes  No
Suggested vascular access   Femoral 
 Right /  Left
 Radial 
 Right /  Left 
 Other
Suggested type of stent  DES  BMS  
Signature of physician on ward   .............................................................................. 
Æ
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Second part
Patient preparation for the procedure 
Peripheral venous catheter  Yes  No
Shaving and pre-disinfection of procedural area  Yes  No 
Complete documentation of patient before transfer to cath-lab  Yes  No 
Patient fasting  Yes  No 
Patient urinated before procedure  Yes  No 
Antibiotics given  Yes  No 
Nurse’s signature on ward     .............................................................................
Patient reception in catheterisation/electrophysiology laboratory
Nurse’s signature    ……………………….................. Operator’s signature     ………………………………................
Third part
Catheterisation/Electrophysiology laboratory
Procedure performed  Coronary angiography  Pressure measurement  Biopsy
 PCI  ICD implantation  BIV-ICD implantation
 EP test and ablation  Stimulator implantation  Other 
Vascular access used: Left site Right site  
Femoral artery  Yes …….  Yes ……. 
Radial artery  Yes …….  Yes ……. 
Femoral vein  Yes …….  Yes ……. 
Jugular vein  Yes …….  Yes ……. 
Other  Yes …….  Yes ……. 
  No complications  Complications 
Local complications in Laboratory …………………………………………………….....................................................................................
…………………………………………………….....................................................................................
General complications in Laboratory …………………………………………………….....................................................................................
…………………………………………………….....................................................................................
Sheath removed  Yes  No 
 Manually  Starclose  Exoseal 
Sheath to be removed after  6 h  12 h  Other ……............
Pressure dressing for   6 h from…......  12 h from…......  Other ……....... from ...............
Comments ……………………………………………………..................................................................................
Operator’s signature    ………………………….........................
Æ
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Związek wprowadzenia karty bezpieczeństwa  
w pracowni hemodynamicznej z redukcją  
liczby powikłań okołozabiegowych
Michał Hawranek1, Paweł M. Gąsior, Piotr Buchta, Marek Gierlotka, Krystyna Czapla,  
Mateusz Tajstra, Łukasz Pyka, Andrzej Lekston, Lech Poloński, Mariusz Gąsior
III Klinika Kardiologii, Śląski Uniwersytet Medyczny, Śląskie Centrum Chorób Serca, Zabrze
S t r e s z c z e n i e
Wstęp: Współczesne oddziały kardiologii wyposażone w pracownię hemodynamiki i elektroterapii muszą stawić czoła ros-
nącym wymaganiom związanym z dynamicznym rozwojem zarówno procedur przezskórnych, jak i elektrofizjologicznych, 
które wiążą się z ryzykiem wystąpienia wielu komplikacji. 
Cel: Celem badania była ocena skuteczności i zasadności wprowadzenia karty bezpieczeństwa okołozabiegowego w prewencji 
niekorzystnych zdarzeń wśród pacjentów poddanych planowej inwazyjnej diagnostyce i leczeniu.
Metody: Przeanalizowano dane 2064 pacjentów skierowanych do leczenia w okresie od maja 2011 r. do sierpnia 2012 r. 
Chorzy, którzy byli hospitalizowani bez inwazyjnej diagnostyki lub leczenia, nie zostali włączeni do badania. Pacjentów 
podzielono na dwie grupy: grupę kontrolną — 1011 chorych poddanych inwazyjnej diagnostyce i terapii przed wprowadze-
niem okołozabiegowej karty bezpieczeństwa; grupę badaną — 1053 chorych poddanych inwazyjnej diagnostyce i terapii po 
wprowadzeniu okołozabiegowej karty bezpieczeństwa. W badanych grupach przeanalizowano występowanie niekorzystnych 
zdarzeń związanych z hospitalizacją i wykonanymi procedurami. Przeprowadzono również subiektywną analizę karty bez-
pieczeństwa przez zespół medyczny na podstawie anonimowego kwestionariusza.
Wyniki: Wyjściowa charakterystyka między badanymi grupami była porównywalna, z wyjątkiem wyższego odsetka stabilnej 
choroby wieńcowej (50,7% vs. 39,6%; p £ 0,001) oraz zabiegów elektrofizjologicznych w grupie kontrolnej. Wprowadzenie 
karty bezpieczeństwa miało korzystny wpływ na zredukowanie niekorzystnych zdarzeń sercowo-naczyniowych (6,8% vs. 3,9%; 
p = 0,004), zwłaszcza krwawień (2,3% vs. 0,3%; p < 0,001). W analizie wieloczynnikowej brak okołozabiegowej karty 
bezpieczeństwa był niezależnym czynnikiem wpływającym na wystąpienie niekorzystnych zdarzeń sercowo-naczyniowych 
(OR = 2,97; 95% CI 1,60–5,53; p = 0,001). Subiektywna ocena opinii personelu medycznego pokazała, że wprowadzenie 
karty bezpieczeństwa koreluje z poprawą zdolności komunikacyjnych, organizacją pracy, zapobieganiem występowania 
błędów medycznych i zredukowanej liczby kompilacji związanych z przeprowadzonymi zabiegami.
Wnioski: Wprowadzenie okołozabiegowej karty bezpieczeństwa wiązało się z istotną redukcją niekorzystnych zdarzeń 
sercowo-naczyniowych wśród pacjentów poddanych zabiegom inwazyjnym. Miała także pozytywny wpływ na komunikację 
w zespole, organizację i jakość leczenia w opinii personelu medycznego.
Słowa kluczowe: komplikacje, krwawienia, przezskórne interwencje wieńcowe
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